NDATOPICALCREAM
Approved
Dec 2017
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
6
Data completeness
3/8 — Basic
Drug data last refreshed 11h ago · AI intelligence enriched 5d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
XEPI (ozenoxacin) is a topical fluoroquinolone cream approved in 2017 for the treatment of bacterial skin infections. It is a novel nonfluorinated quinolone designed for enhanced skin penetration and efficacy in localized dermatological infections. The drug works by inhibiting bacterial DNA gyrase and topoisomerase IV.
Peak5.4 years to LOE
Peak-stage lifecycle suggests stable commercial operations with established market presence, though team growth is unlikely without indication expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (6)
Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy
Started Nov 2014
275 enrolled
Acute Oral Mucositis Pain
Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo
Started Jun 2014
412 enrolled
Impetigo
Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo
Started Mar 2012
465 enrolled
Impetigo
Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy
Started Dec 2010
155 enrolled
Head and Neck CancerMucositisOral Complications of Radiation Therapy+1 more
Safety and Efficacy of Ramelteon and Doxepin in Subjects With Chronic Insomnia
Started Jul 2006
472 enrolled
Sleep Initiation and Maintenance Disorders
Worked on XEPI at Quantum Genomics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.